Abstract Number: 456 • 2013 ACR/ARHP Annual Meeting
Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor -á Antagonist
Background/Purpose: Fostamatinib (Fosta) is an oral SYK inhibitor. This 24-wk study (NCT01197755) compared Fosta vs placebo (PBO) on methotrexate (MTX) treatment in patients (pts) with…Abstract Number: 458 • 2013 ACR/ARHP Annual Meeting
High Levels Of Natural Killer CELLS ARE Associated With Response To Tocilizumab In Patients With Severe Rheumatoid Arthritis
Background/Purpose: Inhibition of interleukin 6 (IL-6) receptor with tocilizumab (TCZ) is effective for rheumatoid arthritis (RA). However, the effect of TCZ on lymphocytes remains poorly…Abstract Number: 459 • 2013 ACR/ARHP Annual Meeting
Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis
Background/Purpose: The interleukin-6 receptor inhibitor tocilizumab (TCZ) has demonstrated efficacy in improving signs/symptoms, reducing joint damage, and improving function and is well tolerated in patients…Abstract Number: 420 • 2013 ACR/ARHP Annual Meeting
Lean Body Mass (LBM) Distribution Negatively Impacts On Health Related Quality Of Life (HRQoL) In Patients With Rheumatoid Arthritis (RA)
Background/Purpose: Sarcopenia is more frequent in RA patients than in general population, probably due to persistent inflammatory state. The impact of inflammatory burden seem to…Abstract Number: 421 • 2013 ACR/ARHP Annual Meeting
Enhanced Cardiovascular Risk Factor Screening In Rheumatoid Arthritis: Does This Have a Sustained Impact?
Background/Purpose: Rheumatoid Arthritis (RA) patients face a burden of cardiovascular disease (CVD) twice that of the general population. RA patients have reduced physical fitness, a…Abstract Number: 422 • 2013 ACR/ARHP Annual Meeting
Disease Activity In Rheumatoid Arthritis Is Associated With Abnormal Left Ventricular Geometry
Background/Purpose :Disease activity is related to risk of cardiovascular (CV) disease in rheumatoid arthritis (RA) patients1,2. Left ventricular (LV) geometry strongly predicts CV mortality and…Abstract Number: 423 • 2013 ACR/ARHP Annual Meeting
Serological Biomarkers For The Development Of Rheumatoid Arthritis Related Interstitial Lung Disease
Background/Purpose: Interstitial Lung Disease (ILD) is the commonest manifestation of lung disease in Rheumatoid Arthritis (RA) and the only complication reported to be increasing in…Abstract Number: 424 • 2013 ACR/ARHP Annual Meeting
2-Year Results From The Ample (Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: Changes In Patient-Reported Outcomes In Response To Subcutaneous Abatacept Or Adalimumab In Rheumatoid Arthritis
Background/Purpose: RA is a debilitating disease that can impact health-related quality of life (HRQoL) through impairment of activity, loss of independence and reduced work productivity.…Abstract Number: 425 • 2013 ACR/ARHP Annual Meeting
Efficacy, Pharmacokinetics, and Safety of Different Doses of Methotrexate in Combination With Adalimumab: Results From the Concerto Trial
Background/Purpose: Anti-TNF plus methotrexate (MTX) is more effective than either as monotherapy. Thus far, no controlled data are available on the benefit:risk of different doses…Abstract Number: 426 • 2013 ACR/ARHP Annual Meeting
Characteristics of Protocol-Specified Responders/Non-Responders Treated With Etanercept Plus Methotrexate in Period 1 of the Prize Study
Background/Purpose: Although frequently effective, treatment with synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) does not adequately control disease activity in all patients. Prompt identification of…Abstract Number: 427 • 2013 ACR/ARHP Annual Meeting
US Veterans With Rheumatoid Arthritis Who Switch Among Tumor Necrosis Factor Blocking Agents Have No Additional Clinical Benefit With The Change In Therapy and Incur Higher Costs
Background/Purpose: While tumor necrosis factor (TNF) blockers can be effective in treating rheumatoid arthritis (RA), the benefit of switching among TNF blockers is not clear.…Abstract Number: 428 • 2013 ACR/ARHP Annual Meeting
Correlation Between Objective and Patient Self-Reported Clinical Improvement After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: Data From Repeat Study
Background/Purpose: Rituximab (RTX) has been evaluated in many clinical trials and objective assessment of rheumatoid arthritis (RA) activity must comply with Treat to Target principles.…Abstract Number: 429 • 2013 ACR/ARHP Annual Meeting
Sustained Clinical Efficacy After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: 2-Year Data From the Repeat (Repeated Courses in Routine Clinical Practice) Study
Background/Purpose: In the last decade, biologic therapy changed dramatically treatment options for rheumatoid arthritis (RA). However, a significant number of patients failed to maintain the…Abstract Number: 430 • 2013 ACR/ARHP Annual Meeting
Comparing abatacept to Adalimumab, Etanercept and Infliximab As First Or Second Line Agents in Patients With Rheumatoid arthritis: Experience From the rhumadata® Clinical Database and Registry
Background/Purpose: The order of use of biologic agents is still a question for debate. Phase III trial data in MTX-IR patients show comparable efficacy results…Abstract Number: 431 • 2013 ACR/ARHP Annual Meeting
Prediction Of Week 52 Treatment Response Based On A Week 12 Assessment In Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Comparison Of A Patient-Reported Instrument Versus Physician-Based Disease Activity Assessment
Background/Purpose: Guidelines support early intervention in rheumatoid arthritis (RA).1,2 The aim was to prospectively test whether outcome assessment at 12 weeks (wks) using a patient-reported…
ACR Meeting Abstracts